Suppr超能文献

一项前瞻性、多中心队列研究,旨在评估巴西选定社区家庭登革热发病情况(2014-2018 年)。

A prospective, multicentre, cohort study to assess the incidence of dengue illness in households from selected communities in Brazil (2014-2018).

机构信息

Instituto de Tecnologia em Imunobiológicos Bio-Manguinhos/Fiocruz, Avenida Brasil 4.365, Manguinhos, Rio de Janeiro - RJ, 21.040-900, Brazil.

GSK, Estrada dos Bandeirantes, 8464, Jacarepaguá, Rio de Janeiro - RJ, 22775-610, Brazil.

出版信息

Int J Infect Dis. 2021 Jul;108:443-453. doi: 10.1016/j.ijid.2021.04.062. Epub 2021 Apr 21.

Abstract

OBJECTIVES

To estimate the incidence of dengue infection across geographically distinct areas of Brazil.

METHODS

This prospective, household-based, cohort study enrolled participants in five areas and followed them up for up to 4 years (2014-2018). Dengue seroprevalence was assessed at each scheduled visit. Suspected dengue cases were identified through enhanced passive and active surveillance. Acute symptomatic dengue infection was confirmed through reverse-transcriptase quantitative polymerase chain reaction in combination with an antigenic assay (non-structural protein 1) and serology.

RESULTS

Among 3300 participants enrolled, baseline seroprevalence was 76.2%, although only 23.3% of participants reported a history of dengue. Of 1284 suspected symptomatic dengue cases detected, 50 (3.9%) were laboratory-confirmed. Based on 8166.5 person-years (PY) of follow-up, the incidence of laboratory-confirmed symptomatic infection (primary endpoint) was 6.1 per 1000 PY (95% confidence interval [CI]: 4.5, 8.1). Incidence varied substantially in different years (1.8-7.4 per 1000 PY). The incidence of inapparent primary dengue infection was substantially higher: 41.7 per 1000 PY (95% CI: 31.1, 54.6).

CONCLUSIONS

Our findings, highlighting that the incidence of dengue infection is underestimated in Brazil, will inform the design and implementation of future dengue vaccine trials.

CLINICAL TRIAL REGISTRATION

NCT01751139.

摘要

目的

估计巴西不同地理区域登革热感染的发生率。

方法

本前瞻性、基于家庭的队列研究纳入了五个地区的参与者,并对他们进行了长达 4 年(2014-2018 年)的随访。在每次预约时评估登革热血清流行率。通过加强的被动和主动监测来发现疑似登革热病例。通过逆转录定量聚合酶链反应结合抗原检测(非结构蛋白 1)和血清学来确认急性症状性登革热感染。

结果

在纳入的 3300 名参与者中,基线血清流行率为 76.2%,尽管只有 23.3%的参与者报告有登革热病史。在检测到的 1284 例疑似有症状的登革热病例中,有 50 例(3.9%)经实验室确诊。在 8166.5 人年(PY)的随访中,实验室确诊的有症状感染(主要终点)的发生率为每 1000 PY 6.1 例(95%置信区间[CI]:4.5,8.1)。不同年份的发病率差异很大(1.8-7.4 例/1000 PY)。无症状原发性登革热感染的发生率要高得多:每 1000 PY 41.7 例(95%CI:31.1,54.6)。

结论

我们的研究结果强调了巴西对登革热感染的发病率估计不足,这将为未来登革热疫苗试验的设计和实施提供信息。

临床试验注册

NCT01751139。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验